The SPECIFY study is a non-interventional study aiming to develop a complex score composed by clinical data, genomic data and protein biomarkers to early predict patients with infection by Clostridium difficile at high likelihood to develop organ failure, relapse of the infection or die.
Study title: “Scoring PErsonalized needs in Clostridium difficile Infections for Fidaxomixin therapY”.
Duration: September 2015 to December 2016
Study phase: II
Number of Study sites: 11
Total number of enrolled patients: 153